Friday, December 29, 2023
Neurolief, a global leader in medical devices known for pioneering neurotechnology solutions addressing Neurological and Neuropsychiatric disorders, is excited to announce a strategic equity investment from Sawai Group Holdings Co., Ltd.
This investment solidifies the strategic collaboration between Neurolief and the Japanese pharmaceutical corporation, following their exclusive agreement for developing and marketing Relivion®. Relivion® is an innovative, non-invasive, at-home wearable electroceutical therapy designed for treating migraine and depression in Japan.
This partnership reflects our dedication to enhancing lives by introducing novel and advanced treatment options. The introduction of Relivion® for at-home treatment, supervised by healthcare professionals, expands choices for patients dealing with migraine or depression.
Source: prnewswier.com
